Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases.

Njar VC, Gediya L, Purushottamachar P, Chopra P, Vasaitis TS, Khandelwal A, Mehta J, Huynh C, Belosay A, Patel J.

Bioorg Med Chem. 2006 Jul 1;14(13):4323-40. Epub 2006 Mar 10. Review.

PMID:
16530416
2.
3.

Prospective teratology of retinoic acid metabolic blocking agents (RAMBAs) and loss of CYP26 activity.

McCaffery P, Simons C.

Curr Pharm Des. 2007;13(29):3020-37. Review.

PMID:
17979744
4.

Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.

Patel JB, Huynh CK, Handratta VD, Gediya LK, Brodie AM, Goloubeva OG, Clement OO, Nanne IP, Soprano DR, Njar VC.

J Med Chem. 2004 Dec 30;47(27):6716-29.

PMID:
15615521
5.

Molecular recognition of CYP26A1 binding pockets and structure-activity relationship studies for design of potent and selective retinoic acid metabolism blocking agents.

Sun B, Song S, Hao CZ, Huang WX, Liu CC, Xie HL, Lin B, Cheng MS, Zhao DM.

J Mol Graph Model. 2015 Mar;56:10-9. doi: 10.1016/j.jmgm.2014.11.014. Epub 2014 Dec 8.

PMID:
25541526
6.

Synthesis of LIAZAL, a retinoic acid metabolism blocking agent (RAMBA) with potential clinical applications in oncology and dermatology.

Freyne E, Raeymaekers A, Venet M, Sanz G, Wouters W, De Coster R, Wauwe JV.

Bioorg Med Chem Lett. 1998 Feb 3;8(3):267-72.

PMID:
9871667
7.
9.

Design, synthesis, and biological evaluation of amide imidazole derivatives as novel metabolic enzyme CYP26A1 inhibitors.

Sun B, Liu K, Han J, Zhao LY, Su X, Lin B, Zhao DM, Cheng MS.

Bioorg Med Chem. 2015 Oct 15;23(20):6763-73. doi: 10.1016/j.bmc.2015.08.019. Epub 2015 Aug 20.

PMID:
26365710
10.

Effect of NADPH-cytochrome P450 reductase on all-trans-retinoic acid efficacy and cytochrome P450 26A1 expression in human myeloid leukaemia HL-60 cells.

Hu L, Lv JF, Zhuo W, Zhang CM, Zhou HH, Fan L.

J Pharm Pharmacol. 2016 Sep;68(9):1193-202. doi: 10.1111/jphp.12591. Epub 2016 Jul 1.

PMID:
27366899
12.

Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity.

Quere R, Baudet A, Cassinat B, Bertrand G, Marti J, Manchon L, Piquemal D, Chomienne C, Commes T.

Blood. 2007 May 15;109(10):4450-60. Epub 2007 Jan 11.

13.

Role of Retinoic Acid-Metabolizing Cytochrome P450s, CYP26, in Inflammation and Cancer.

Stevison F, Jing J, Tripathy S, Isoherranen N.

Adv Pharmacol. 2015;74:373-412. doi: 10.1016/bs.apha.2015.04.006. Epub 2015 May 27. Review.

14.

All trans retinoic acid and cancer.

Siddikuzzaman, Guruvayoorappan C, Berlin Grace VM.

Immunopharmacol Immunotoxicol. 2011 Jun;33(2):241-9. doi: 10.3109/08923973.2010.521507. Epub 2010 Oct 8. Review.

PMID:
20929432
15.
16.

Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics.

Nelson CH, Buttrick BR, Isoherranen N.

Curr Top Med Chem. 2013;13(12):1402-28. Review.

17.

All-trans-retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes.

Adedoyin A, Stiff DD, Smith DC, Romkes M, Bahnson RC, Day R, Hofacker J, Branch RA, Trump DL.

Cancer Chemother Pharmacol. 1998;41(2):133-9.

PMID:
9443626
18.

Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents.

Patel JB, Khandelwal A, Chopra P, Handratta VD, Njar VC.

Cancer Chemother Pharmacol. 2007 Nov;60(6):899-905. Epub 2007 Mar 8.

PMID:
17345084
19.

First chemical feature-based pharmacophore modeling of potent retinoidal retinoic acid metabolism blocking agents (RAMBAs): identification of novel RAMBA scaffolds.

Purushottamachar P, Patel JB, Gediya LK, Clement OO, Njar VC.

Eur J Med Chem. 2012 Jan;47(1):412-23. doi: 10.1016/j.ejmech.2011.11.010. Epub 2011 Nov 17.

20.

Synthesis and CYP26A1 inhibitory activity of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates.

Gomaa MS, Lim AS, Lau SC, Watts AM, Illingworth NA, Bridgens CE, Veal GJ, Redfern CP, Brancale A, Armstrong JL, Simons C.

Bioorg Med Chem. 2012 Oct 15;20(20):6080-8. doi: 10.1016/j.bmc.2012.08.044. Epub 2012 Aug 30.

PMID:
22989911

Supplemental Content

Support Center